AIMS: To determine the occurrence of microalbuminuria in young people with Type 1 diabetes mellitus followed prospectively for 2 years and to relate the presence of persistent elevations in urinary albumin excretion (UAE) to age, diabetes duration, puberty and other factors. METHODS: During a 2 year period, random urine samples were obtained from 471 patients, aged 8-18 years (mean +/-sd 12.9 +/- 2.3 years) with Type 1 diabetes duration 5.6 +/- 3.0 years, as part of routine clinical care. Urine albumin and creatinine concentrations were measured in 1310 samples (median, 3 samples per patient) and the albumin:creatinine ratio was calculated (in micrograms albumin per milligram creatinine). Height, weight, blood pressure (BP), glycated haemoglobin (HbA(1c)), blood glucose monitoring frequency and Tanner staging were collected from patients' medical records. RESULTS: Twenty-three per cent of patients had one or more sample with elevated UAE (> or =20 microg/mg) and 9.3% had persistent elevations (> or =2 samples > or =20 microg/mg). Those with and without persistent microalbuminuria did not differ significantly in age, diabetes duration, z-score for body mass index, pubertal status or BP percentile. Ten per cent of children <13 years old and 9% of children > or =13 years old had persistent microalbuminuria. Persistent microalbuminuria was significantly associated with diabetes duration only in older children (duration 0.5-3 years, 4%; 4-6 years, 8%; > or =7 years, 14%; P = 0.02, trend test). Mean HbA(1c) over the 2 years was 8.7 +/- 1.2%. In a logistic regression model, mean HbA(1c) was the only significant predictor of persistent microalbuminuria (odds ratio 1.3, 95% confidence interval 1.0-1.6, P = 0.05). CONCLUSIONS: Microalbuminuria in older children with Type 1 diabetes is likely to be clinically significant. In younger children, it may reflect functional, reversible renal changes. Longitudinal analysis is needed to confirm the probable transient nature of microalbuminuria in young patients with Type 1 diabetes.
AIMS: To determine the occurrence of microalbuminuria in young people with Type 1 diabetes mellitus followed prospectively for 2 years and to relate the presence of persistent elevations in urinary albumin excretion (UAE) to age, diabetes duration, puberty and other factors. METHODS: During a 2 year period, random urine samples were obtained from 471 patients, aged 8-18 years (mean +/-sd 12.9 +/- 2.3 years) with Type 1 diabetes duration 5.6 +/- 3.0 years, as part of routine clinical care. Urine albumin and creatinine concentrations were measured in 1310 samples (median, 3 samples per patient) and the albumin:creatinine ratio was calculated (in micrograms albumin per milligram creatinine). Height, weight, blood pressure (BP), glycated haemoglobin (HbA(1c)), blood glucose monitoring frequency and Tanner staging were collected from patients' medical records. RESULTS: Twenty-three per cent of patients had one or more sample with elevated UAE (> or =20 microg/mg) and 9.3% had persistent elevations (> or =2 samples > or =20 microg/mg). Those with and without persistent microalbuminuria did not differ significantly in age, diabetes duration, z-score for body mass index, pubertal status or BP percentile. Ten per cent of children <13 years old and 9% of children > or =13 years old had persistent microalbuminuria. Persistent microalbuminuria was significantly associated with diabetes duration only in older children (duration 0.5-3 years, 4%; 4-6 years, 8%; > or =7 years, 14%; P = 0.02, trend test). Mean HbA(1c) over the 2 years was 8.7 +/- 1.2%. In a logistic regression model, mean HbA(1c) was the only significant predictor of persistent microalbuminuria (odds ratio 1.3, 95% confidence interval 1.0-1.6, P = 0.05). CONCLUSIONS: Microalbuminuria in older children with Type 1 diabetes is likely to be clinically significant. In younger children, it may reflect functional, reversible renal changes. Longitudinal analysis is needed to confirm the probable transient nature of microalbuminuria in young patients with Type 1 diabetes.
Authors: Rakesh Amin; Rachel M Williams; January Frystyk; Margot Umpleby; David Matthews; Hans Orskov; R Neil Dalton; David B Dunger Journal: Clin Endocrinol (Oxf) Date: 2005-02 Impact factor: 3.478
Authors: Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Vital Health Stat 11 Date: 2002-05
Authors: Birthe S Olsen; Anne Katrin Sjølie; Philip Hougaard; Jesper Johannesen; Karin Marinelli; Bent Brock Jacobsen; Henrik B Mortensen Journal: J Diabetes Complications Date: 2004 May-Jun Impact factor: 2.852
Authors: Bruce A Perkins; Linda H Ficociello; Kristen H Silva; Dianne M Finkelstein; James H Warram; Andrzej S Krolewski Journal: N Engl J Med Date: 2003-06-05 Impact factor: 91.245
Authors: Dana Y Fuhrman; Michael F Schneider; Katherine M Dell; Tom D Blydt-Hansen; Robert Mak; Jeffrey M Saland; Susan L Furth; Bradley A Warady; Marva M Moxey-Mims; George J Schwartz Journal: Clin J Am Soc Nephrol Date: 2017-05-25 Impact factor: 8.237
Authors: Vicki S Helgeson; Dianne K Palladino; Kerry A Reynolds; Dorothy J Becker; Oscar Escobar; Linda Siminerio Journal: Health Psychol Date: 2013-08-05 Impact factor: 4.267
Authors: Petter Bjornstad; Edward Nehus; Laure El Ghormli; Fida Bacha; Ingrid M Libman; Siripoom McKay; Steven M Willi; Lori Laffel; Silva Arslanian; Kristen J Nadeau Journal: Am J Kidney Dis Date: 2017-11-20 Impact factor: 8.860
Authors: Tina Costacou; Jamie Crandell; Anna R Kahkoska; Angela D Liese; Dana Dabelea; Jean M Lawrence; David J Pettitt; Kristi Reynolds; Elizabeth J Mayer-Davis; Amy K Mottl Journal: Diabetes Care Date: 2018-06-14 Impact factor: 19.112
Authors: Mark Daniels; Stephanie N DuBose; David M Maahs; Roy W Beck; Larry A Fox; Rose Gubitosi-Klug; Lori M Laffel; Kellee M Miller; Heather Speer; William V Tamborlane; Michael J Tansey Journal: Diabetes Care Date: 2013-04-22 Impact factor: 19.112